Bicara Therapeutics Inc (BCAX)

Jun 3, 2025, 4:01 PM EDT - 2 days ago

Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 1, 2025, 1:12 PM EDT - 4 days ago

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

May 23, 2025, 4:17 PM EDT - 13 days ago

Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

May 22, 2025, 5:00 PM EDT - 14 days ago

Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting

May 13, 2025, 7:30 AM EDT - 24 days ago

Bicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:01 PM EDT - 5 weeks ago

Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025

Apr 23, 2025, 10:00 AM EDT - 6 weeks ago

Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 19, 2025, 6:22 AM EDT - 6 weeks ago

Bicara: Innovative Precision Tumor Targeting

Mar 27, 2025, 7:30 AM EDT - 2 months ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 25, 2025, 4:45 PM EDT - 2 months ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Feb 24, 2025, 4:01 PM EST - 3 months ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 11, 2025, 4:01 PM EST - 4 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jan 27, 2025, 8:00 AM EST - 4 months ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Nov 12, 2024, 7:30 AM EST - 7 months ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 11, 2024, 4:01 PM EST - 7 months ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:01 PM EDT - 9 months ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 14, 2024, 5:00 AM EDT - 9 months ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

GLXG MBX TDTH XCH ZBIO

Sep 13, 2024, 1:28 PM EDT - 9 months ago

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Sep 12, 2024, 9:15 PM EDT - 9 months ago

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Sep 11, 2024, 6:34 PM EDT - 9 months ago

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Sep 7, 2024, 1:25 AM EDT - 9 months ago

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

BIOA PMAX PTHL ZBIO

Sep 6, 2024, 7:25 AM EDT - 9 months ago

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Aug 27, 2024, 2:19 PM EDT - 10 months ago

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

Aug 22, 2024, 5:29 PM EDT - 10 months ago

Oncology biotech Bicara Therapeutics files for a $200 million IPO

Aug 22, 2024, 4:38 PM EDT - 10 months ago

Bicara Therapeutics IPO Registration Document (S-1)